Inspire Medical Systems (NYSE:INSP) Releases FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 1.200-1.400 for the period, compared to the consensus EPS estimate of 1.250. The company issued revenue guidance of $850.0 million-$860.0 million, compared to the consensus revenue estimate of $853.6 million.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on INSP shares. JPMorgan Chase & Co. boosted their target price on shares of Inspire Medical Systems from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday. Oppenheimer raised Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a report on Tuesday, August 4th. KeyCorp restated a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Royal Bank Of Canada lifted their price objective on Inspire Medical Systems from $60.00 to $75.00 and gave the stock a “sector perform” rating in a report on Thursday, October 1st. Finally, Piper Sandler upped their price objective on Inspire Medical Systems from $60.00 to $70.00 and gave the company a “neutral” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inspire Medical Systems presently has a consensus rating of “Hold” and a consensus target price of $71.24.

Inspire Medical Systems Trading Down 7.8%

INSP opened at $62.00 on Wednesday. The firm’s 50 day simple moving average is $68.70 and its two-hundred day simple moving average is $58.66. The company has a market capitalization of $1.79 billion, a PE ratio of 33.11, a PEG ratio of 5.08 and a beta of 0.67. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $206.69 million during the quarter, compared to the consensus estimate of $204.31 million. Inspire Medical Systems had a net margin of 11.43% and a return on equity of 7.38%. The company’s revenue for the quarter was down 7.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.38 EPS. Equities analysts forecast that Inspire Medical Systems will post 1.24 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 2.20% of the company’s stock.

Inspire Medical Systems News Summary

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q3 adjusted earnings of $0.14 per share and revenue of about $206.7 million topped consensus estimates of $0.09 and $204.3 million, respectively. Article: Inspire Medical Systems Q3 Earnings and Revenues Beat Estimates
• Neutral Sentiment: For FY 2026, Inspire guided to EPS of $1.20–$1.40 and revenue of $850–$860 million, broadly around analysts’ estimates. The company also plans to present at the Stifel Healthcare Conference on November 10. Article: Inspire Narrows Full-Year 2026 Earnings Guidance
• Neutral Sentiment: Analyst target changes were mixed: Baird and Piper Sandler raised targets, JPMorgan increased its target while retaining a neutral rating, and Barclays lowered its target and kept an underweight rating.
• Negative Sentiment: Revenue fell 7.9% year over year, while EPS declined from $0.38 a year earlier. Reports said the results missed investor “whisper” expectations, and management projected only low-single-digit revenue growth in 2027 as reimbursement and coding trends stabilize—signs of a slower recovery that may weigh more heavily than the quarterly beat. Article: Inspire Medical Stock Drops Despite Beating Q3 Expectations Article: Inspire Projects Low-Single-Digit 2027 Revenue Growth

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.